View Future GrowthAnshan Hifichem 過去の業績過去 基準チェック /06Anshan Hifichemの収益は年間平均-17.1%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間5.6% 5.6%割合で 増加しています。 Anshan Hifichemの自己資本利益率は2.4%であり、純利益率は3%です。主要情報-17.13%収益成長率-20.12%EPS成長率Chemicals 業界の成長12.10%収益成長率5.57%株主資本利益率2.43%ネット・マージン3.02%次回の業績アップデート22 Aug 2026最近の業績更新お知らせ • Jun 30Anshan Hifichem Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Anshan Hifichem Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025すべての更新を表示Recent updatesお知らせ • Jun 30Anshan Hifichem Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Anshan Hifichem Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026New Risk • May 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.1% operating cash flow to total debt). Earnings have declined by 17% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin).お知らせ • Apr 24Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning Chinaお知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Apr 18Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning Chinaお知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2023). Revenue: CN¥415.5m (up 31% from 3Q 2023). Net income: CN¥53.0m (up CN¥45.1m from 3Q 2023). Profit margin: 13% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 31%After last week's 31% share price gain to CN¥13.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 35% over the past year.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.8% average weekly change).お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anshan Hifichem Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024お知らせ • Sep 21Anshan Hifichem Co., Ltd. Announces 2024 Interim Profit Distribution Plan (A Shares),Payable September 26, 2024Anshan Hifichem Co., Ltd. announced 2024 interim profit distribution plan to be implemented (A shares):Cash dividend/10 shares (tax included): CNY0.50000000. Record date: 25 September 2024, Ex-date: 26 September 2024, Payment date: 26 September 2024.New Risk • Sep 07New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.007 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.007 in 2Q 2023). Revenue: CN¥416.2m (up 35% from 2Q 2023). Net income: CN¥45.6m (up CN¥42.6m from 2Q 2023). Profit margin: 11% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Jun 29Anshan Hifichem Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024Anshan Hifichem Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024Reported Earnings • Apr 16First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.05 (up from CN¥0.04 loss in 1Q 2023). Revenue: CN¥322.5m (up 22% from 1Q 2023). Net income: CN¥21.6m (up CN¥36.4m from 1Q 2023). Profit margin: 6.7% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China.New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Large one-off items impacting financial results.お知らせ • Mar 30Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024Anshan Hifichem Co., Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024お知らせ • Feb 09Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning ChinaNew Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results.Reported Earnings • Feb 07Full year 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.01 loss in FY 2022)Full year 2023 results: EPS: CN¥0.03 (up from CN¥0.01 loss in FY 2022). Revenue: CN¥1.22b (flat on FY 2022). Net income: CN¥11.0m (up CN¥13.8m from FY 2022). Profit margin: 0.9% (up from net loss in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.New Risk • Feb 07New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Dec 29Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2023 results on Feb 29, 2024New Risk • Dec 22New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.021 (up from CN¥0.009 loss in 3Q 2022). Revenue: CN¥317.7m (up 7.1% from 3Q 2022). Net income: CN¥7.96m (up CN¥10.6m from 3Q 2022). Profit margin: 2.5% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Anshan Hifichem Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.007 (up from CN¥0.002 in 2Q 2022). Revenue: CN¥308.0m (flat on 2Q 2022). Net income: CN¥2.96m (up 188% from 2Q 2022). Profit margin: 1.0% (up from 0.3% in 2Q 2022).Reported Earnings • Apr 26First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)First quarter 2023 results: CN¥0.04 loss per share (down from CN¥0.06 profit in 1Q 2022). Revenue: CN¥263.6m (down 18% from 1Q 2022). Net loss: CN¥14.8m (down 160% from profit in 1Q 2022).Board Change • Mar 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.収支内訳Anshan Hifichem の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XSEC:300758 収益、費用、利益 ( )CNY Millions日付収益収益G+A経費研究開発費31 Mar 261,531462219231 Dec 251,4956121510030 Sep 251,5337821310530 Jun 251,58811020710431 Mar 251,61013420410631 Dec 241,5681252039630 Sep 241,4831351698930 Jun 241,385901788531 Mar 241,277471757731 Dec 231,218111818130 Sep 231,168-301907930 Jun 231,147-401948631 Mar 231,149-421989101 Jan 231,209-31929130 Sep 221,343531819830 Jun 221,370931699231 Mar 221,3611571508801 Jan 221,3471801378230 Sep 211,2481921087330 Jun 211,1931971046631 Mar 211,142187975831 Dec 201,008175875130 Sep 20877141884530 Jun 20774142723831 Mar 20724130793231 Dec 19695108753130 Sep 19661120692730 Jun 19664111672731 Mar 19628100582631 Dec 18611105582530 Sep 18606115532230 Jun 18583110492331 Mar 18550101462231 Dec 17553103452130 Sep 17525100441630 Jun 17498962331031 Mar 1747086145531 Dec 164427657030 Sep 1641960-32030 Jun 1639644-122031 Mar 1638341-33031 Dec 1537039550質の高い収益: 300758にはCN¥36.0M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。利益率の向上: 300758の現在の純利益率 (3%)は、昨年(8.3%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 300758の収益は過去 5 年間で年間17.1%減少しました。成長の加速: 300758は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: 300758は過去 1 年間で収益成長率がマイナス ( -65.6% ) となったため、 Chemicals業界平均 ( 4% ) と比較することが困難です。株主資本利益率高いROE: 300758の 自己資本利益率 ( 2.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/06 21:35終値2026/08/06 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anshan Hifichem Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Nai Di ZhaoEverbright Securities Co. Ltd.Wei LiuHaitong International Research Limited
お知らせ • Jun 30Anshan Hifichem Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Anshan Hifichem Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025
お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025
お知らせ • Jun 30Anshan Hifichem Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Anshan Hifichem Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026
New Risk • May 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.1% operating cash flow to total debt). Earnings have declined by 17% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin).
お知らせ • Apr 24Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025
お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Apr 18Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025
お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2023). Revenue: CN¥415.5m (up 31% from 3Q 2023). Net income: CN¥53.0m (up CN¥45.1m from 3Q 2023). Profit margin: 13% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 31%After last week's 31% share price gain to CN¥13.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 35% over the past year.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.8% average weekly change).
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anshan Hifichem Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
お知らせ • Sep 21Anshan Hifichem Co., Ltd. Announces 2024 Interim Profit Distribution Plan (A Shares),Payable September 26, 2024Anshan Hifichem Co., Ltd. announced 2024 interim profit distribution plan to be implemented (A shares):Cash dividend/10 shares (tax included): CNY0.50000000. Record date: 25 September 2024, Ex-date: 26 September 2024, Payment date: 26 September 2024.
New Risk • Sep 07New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.007 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.007 in 2Q 2023). Revenue: CN¥416.2m (up 35% from 2Q 2023). Net income: CN¥45.6m (up CN¥42.6m from 2Q 2023). Profit margin: 11% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Jun 29Anshan Hifichem Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024Anshan Hifichem Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024
Reported Earnings • Apr 16First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.05 (up from CN¥0.04 loss in 1Q 2023). Revenue: CN¥322.5m (up 22% from 1Q 2023). Net income: CN¥21.6m (up CN¥36.4m from 1Q 2023). Profit margin: 6.7% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China.
New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Large one-off items impacting financial results.
お知らせ • Mar 30Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024Anshan Hifichem Co., Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024
お知らせ • Feb 09Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
New Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Feb 07Full year 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.01 loss in FY 2022)Full year 2023 results: EPS: CN¥0.03 (up from CN¥0.01 loss in FY 2022). Revenue: CN¥1.22b (flat on FY 2022). Net income: CN¥11.0m (up CN¥13.8m from FY 2022). Profit margin: 0.9% (up from net loss in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
New Risk • Feb 07New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Dec 29Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2023 results on Feb 29, 2024
New Risk • Dec 22New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.021 (up from CN¥0.009 loss in 3Q 2022). Revenue: CN¥317.7m (up 7.1% from 3Q 2022). Net income: CN¥7.96m (up CN¥10.6m from 3Q 2022). Profit margin: 2.5% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.
New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Anshan Hifichem Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.007 (up from CN¥0.002 in 2Q 2022). Revenue: CN¥308.0m (flat on 2Q 2022). Net income: CN¥2.96m (up 188% from 2Q 2022). Profit margin: 1.0% (up from 0.3% in 2Q 2022).
Reported Earnings • Apr 26First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)First quarter 2023 results: CN¥0.04 loss per share (down from CN¥0.06 profit in 1Q 2022). Revenue: CN¥263.6m (down 18% from 1Q 2022). Net loss: CN¥14.8m (down 160% from profit in 1Q 2022).
Board Change • Mar 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.